Table 1.
Demographic and baseline characteristics of patients with ICI-induced IDDM.
| Population | 34 Patients |
|---|---|
| Median Age (Range) | 60.5 (39–79) |
| Sex | n (%) |
| Male | 25 (74%) |
| Female | 9 (26%) |
| Primary Tumor | n (%) |
| Melanoma | 19 (56%) |
| Renal cell carcinoma | 4 (12%) |
| Non-small cell lung cancer | 4 (12%) |
| Other 1 | 7 (20%) |
| Comorbidities | n (%) |
| Hypertension | 10 (29%) |
| Dyslipidemia | 10 (29%) |
| Obesity | 3 (9%) |
| NIDDM | 3 (9%) |
| Pre-DM | 4 (12%) |
| Hypothyroidism | 5 (15%) |
| Autoimmune disease 2 | 5 (15%) |
| ICI Regimen | n (%) |
| Anti-PD1/PD-L1 monotherapy | 20 (59%) |
| Anti-PD1/PD-L1 + anti-CTLA4 | 9 (26%) |
| Anti-PD1/PD-L1 + another agent | 3 (9%) |
| Anti-PD1/PD-L1 + another agent/placebo | 2 (6%) |
| Line of Therapy | n (%) |
| First | 16 (47%) |
| Second | 7 (21%) |
| Third or beyond | 6 (17%) |
| Adjuvant | 4 (12%) |
| Consolidation | 1 (3%) |
1: Other tumor types include head and neck squamous cell carcinoma (2), gastroesophageal junction adenocarcinoma, urothelial carcinoma, breast carcinoma, and hepatocellular carcinoma (1 each); 2: autoimmune diseases were psoriasis (2), Crohn’s disease, ulcerative colitis and systemic lupus erythematosus (1 each). CTLA4: cytotoxic T-lymphocyte antigen 4; DM: diabetes mellitus; IDDM: insulin-dependent diabetes mellitus; NIDDM: non-insulin-dependent diabetes mellitus; PD1: programmed death 1; PD-L1: programmed death ligand 1.